CorMedix Inc
NASDAQ:CRMD

  • LAST PRICE
    5.1500
  • TODAY'S CHANGE (%)
    -0.0400 (-0.7707%)
  • Bid / Lots
    5.1500/ 1
  • Ask / Lots
    5.1600/ 3
  • Open / Previous Close
    5.1500 / 5.1900
  • Day Range
    5.0700
    5.1850
  • 52 Week Range
    2.5700
    7.0000
  • Volume
    61,097

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Generic & Specialty Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CRMD
CorMedix Inc
289.8M
-5.5x
---
CPLFY
Cipla Ltd
14.0B
0.0x
---
ZVRA
Zevra Therapeutics Inc
194.6M
-3.5x
---
CALT
Calliditas Therapeutics AB
1.2B
-21.3x
---
ASMB
Assembly Biosciences Inc
83.5M
-1.4x
---
DBVT
Dbv Technologies SA
119.3M
-1.2x
---
As of 2024-06-07

Company Information

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Contact Information

Headquarters
300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
Phone
908-517-9500
Fax
302-636-5454

Executives

Independent Chairman of the Board
Myron Kaplan
Chief Executive Officer, Director
Joseph Todisco
Chief Financial Officer, Executive Vice President
Matthew David
Executive Vice President, Head of Clinical and Medical Affairs
Elizabeth Massonhurlburt
Executive Vice President, Chief Commercial Officer
Erin Mistry

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$289.8M
Revenue (TTM)
$0.00
Shares Outstanding
55.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.73
EPS
$-0.93
Book Value
$1.28
P/E Ratio
-5.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.